Century Therapeutics
IPSC
63 hedge funds and large institutions have $69.5M invested in Century Therapeutics in 2023 Q1 according to their latest regulatory filings, with 15 funds opening new positions, 24 increasing their positions, 16 reducing their positions, and 17 closing their positions.
271% more call options, than puts
Call options by funds: $26K | Put options by funds: $7K
50% more repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 16
1.63% less ownership
Funds ownership: 35.43% → 33.8% (-1.6%)
3% less funds holding
Funds holding: 65 → 63 (-2)
12% less first-time investments, than exits
New positions opened: 15 | Existing positions closed: 17
35% less capital invested
Capital invested by funds: $107M → $69.5M (-$37.4M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
+$3.65M |
| 2 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
+$1.44M |
| 3 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$872K |
| 4 |
NYLIM
New York Life Investment Management
New York
|
+$588K |
| 5 |
Acadian Asset Management
Boston,
Massachusetts
|
+$270K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$7.7M |
| 2 |
HA
HHLR Advisors
Grand Cayman,
Cayman Islands
|
-$2.55M |
| 3 |
Walleye Capital
New York
|
-$784K |
| 4 |
Millennium Management
New York
|
-$673K |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
-$421K |
IPSC Hedge Fund Activity: Q1 2023 in Review
63 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Century Therapeutics (IPSC) for Q1 2023, worth a combined $69.5M — down 35% from $107M a quarter earlier.
Sellers outnumbered buyers: 17 funds closed out of IPSC and 15 opened new positions — a net loss of 2 holders — while 16 trimmed existing stakes and 24 added.
The largest buyer was DAFNA Capital Management, adding an estimated $3.65M. The largest seller was Fidelity Investments, cutting an estimated $7.7M.
- 63 institutional investors held Century Therapeutics (IPSC) as of Q1 2023, down from 65 in Q4 2022.
- Funds reported $69.5M of Century Therapeutics stock for Q1 2023, down 35% quarter-over-quarter.
- 15 funds opened new Century Therapeutics positions in Q1 2023 and 17 closed out, a net change of -2 holders.
- The largest Century Therapeutics buyer in Q1 2023 was DAFNA Capital Management, an estimated $3.65M added.
- The largest Century Therapeutics seller in Q1 2023 was Fidelity Investments, an estimated $7.7M sold.
Based on aggregated 13F filings for Q1 2023.